Aquapharm appoints new Senior Vice President

Aquapharm Biodiscovery Ltd., a leading Scottish marine biotechnology company, today announced the appointment of another prominent industry figure to its team.

Bertrand Lehuu, who has almost 30 years’ experience in senior roles in many of Europe’s biggest pharmaceutical and biotechnology companies, joins Aquapharm as Senior Vice President (SVP) -Pharma Business.

Bertrand is well known as a bio-pharmaceutical deal-maker and will be responsible for business development in this field for Aquapharm.

After gaining his Doctorate of Pharmacology from Paris University, Bertrand has built his career as a Business Development specialist in the Pasteur Institute, Flamel Technologies, F-Hoffmann La Roche Ltd., Basilea, Neuro3d, BioXell and most recently PharmaSwiss.

His new role at Aquapharm marks a return to the cutting-edge of biotechnology in a company focused on discovering and developing new pharmaceutical, personal care and nutritional products from its unique collection of marine micro-organisms.

Bertrand will play a strategic role in the development and future growth of the company which, in the last year alone, has attracted a significant amount of funding and struck several research partnerships.


2010 has seen Aquapharm go from strength-to-strength, securing £4.2 million of funding from existing investors Aescap Venture, Tate & Lyle Ventures, Highlands & Islands Enterprise and NESTA.
Highlighting the diversity and depth of its research, the company has also entered into a collaboration with Albany Molecular Research to identify novel anti-microbial and anti-inflammatory drug-candidates; Dundee University to develop compounds that may help in the fight against Alzheimer’s; and Leatherhead Food Research to identify food preservatives.

Today’s announcement of Aquapharm’s newest recruit is the latest in a series of prominent appointments, latterly that of Mats Pettersson who joined the Board in January this year. In 2010, serial biotech entrepreneur Prof. Simon Best joined the company as CEO, while Dr Tim Morley was named Chief Scientific Officer (CSO) and Aquapharm founder Dr Andrew Mearns Spragg moved to the role of Chief Technology Officer (CTO).
Source: Company release